Office of Health Economics, 7th Floor, Southside, 105 Victoria Street, London, SW1E 6QT, UK.
Arnold Consultancy & Technology, LLC, 15 West 72nd Street-23rd Floor, New York, NY, 10023-3458, USA.
Pharmacoeconomics. 2019 Nov;37(11):1355-1369. doi: 10.1007/s40273-019-00819-z.
Transparency in decision modelling is an evolving concept. Recently, discussion has moved from reporting standards to open-source implementation of decision analytic models. However, in the debate about the supposed advantages and disadvantages of greater transparency, there is a lack of definition. The purpose of this article is not to present a case for or against transparency, but rather to provide a more nuanced understanding of what transparency means in the context of decision modelling and how it could be addressed. To this end, we review and summarise the discourse to date, drawing on our collective experience. We outline a taxonomy of the different manifestations of transparency, including reporting standards, reference models, collaboration, model registration, peer review and open-source modelling. Further, we map out the role and incentives for the various stakeholders, including industry, research organisations, publishers and decision makers. We outline the anticipated advantages and disadvantages of greater transparency with respect to each manifestation, as well as the perceived barriers and facilitators to greater transparency. These are considered with respect to the different stakeholders and with reference to issues including intellectual property, legality, standards, quality assurance, code integrity, health technology assessment processes, incentives, funding, software, access and deployment options, data protection and stakeholder engagement. For each manifestation of transparency, we discuss the 'what', 'why', 'who' and 'how'. Specifically, their meaning, why the community might (or might not) wish to embrace them, whose engagement as stakeholders is required and how relevant objectives might be realised. We identify current initiatives aimed to improve transparency to exemplify efforts in current practice and for the future.
透明度在决策建模中是一个不断发展的概念。最近,讨论已经从报告标准转移到决策分析模型的开源实现。然而,在关于提高透明度的所谓优势和劣势的争论中,缺乏定义。本文的目的不是提出赞成或反对透明度的观点,而是提供一个更细致入微的理解,即在决策建模的背景下透明度意味着什么,以及如何解决这个问题。为此,我们回顾和总结了迄今为止的讨论,借鉴了我们的集体经验。我们概述了透明度的不同表现形式的分类法,包括报告标准、参考模型、协作、模型注册、同行评审和开源建模。此外,我们还描绘了不同利益相关者的角色和激励因素,包括行业、研究组织、出版商和决策者。我们概述了每种表现形式的更高透明度所带来的预期优势和劣势,以及对更高透明度的感知障碍和促进因素。这些都是针对不同的利益相关者,并参考了包括知识产权、合法性、标准、质量保证、代码完整性、卫生技术评估流程、激励、资金、软件、访问和部署选项、数据保护和利益相关者参与等问题来考虑的。对于透明度的每种表现形式,我们讨论了“是什么”、“为什么”、“谁”和“如何”。具体来说,它们的含义、社区为什么(或为什么不)希望接受它们、需要哪些利益相关者的参与以及如何实现相关目标。我们确定了旨在提高透明度的当前举措,以举例说明当前实践和未来的努力。